Who owns Celcuity Inc. (CELC)? Elite investor 13F holders
2 tracked elite investors reported holding Celcuity Inc as of 2026-06-30, including D.E. Shaw, Oaktree Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | CELCUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 9684112.00 USD | 8500000.000000 | Principal | buy | Original filing |
| Oaktree Capital Management | CELCUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 7133750.00 USD | 6250000.000000 | Principal | buy | Original filing |
| D.E. Shaw | CELCUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3179820.00 USD | 30394.000000 | Shares | add | Original filing |
| Polen Capital Management | CELCUITY INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Oaktree Capital Management | CELCUITY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Principal | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.